

Collaboration, Innovation and Scientific Excellence: the European Pharmacopoeia 11th Edition International Conference 19-21 September 2022 Strasbourg, France

# PROGRAMME

Organised by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe on the occasion of the launch of the 11th Edition European Pharmacopoeia

edom

European Directorate for the Quality of Medicines & HealthCare & soins de santé





#### Day 1 - Monday, 19 September 2022

13:30-14:00 Registration 🖋

### OPENING SESSION

14:00-14h10 Welcome Address

Bjørn Berge, Deputy Secretary General, Council of Europe

# 

Moderator: Petra Doerr, EDQM, Council of Europe

14:10-14:15 **Opening Remarks** Petra Doerr, Director, EDQM, Council of Europe

- 14:15-14:45 **The impact of the COVID pandemic: a global perspective** Mariângela Batista Galvão Simão, Assistant Director-General, Access to Medicines and Health Products, World Health Organization (WHO)
- 14:45-15:10 Next challenge for Europe: shaping EU medicines legislation Sylvain Giraud, Head of Unit, Directorate-General for Health and Food Safety, European Commission

15:10-15:40 Coffee break

**Moderator**: Prof. Torbjörn Arvidsson, Former Chair of the European Pharmacopoeia Commission

- 15:40-16:00 **European Pharmacopoeia 11th Edition at a glance** Cathie Vielle, EDQM, Council of Europe
- 16:00-16:20 **Collaboration matters: the work of a National Pharmacopoeia Authority** Tobias Gosdschan, Swissmedic, Switzerland
- 16:20-16:50 **EDQM pan-European networks: success built on trust, complementarity and mutual benefits** Petra Doerr, Director, EDQM, Council of Europe

ഹ

- 16:50-17:20 Moderated Panel Discussion
- 17:20 Close of Day 1

Day 2 - Morning - Tuesday, 20 September 2022						
08:00-08:30 Welcome FEATURED SESSIONS 08:30-10:30 Four sessions will run in parallel. Interpretation into French will not be provided during the featured sessions.						
Session 1A Session 2 Session 3 Session 4						
Flexibility in the Ph. Eur.: a paradigm shift? (Part I)	Challenges related to the control of impurities in complex APIs and excipients	Herbals	Pharmacopoeial Harmonisation			
Auditorium: Cassin	Room: Londres 1	Room: Madrid 1	Room: Amsterdam			
<ul> <li>Moderator: Prof. Torbjörn Arvidsson, Former Chair of the European Pharmacopoeia Commission</li> <li>Flexibility in general texts of the Ph. Eur.</li> <li>Bruno Spieldenner, EDQM, Council of Europe</li> <li>Continuous manufacturing and Ph. Eur.: PAT chapter and related topics</li> </ul>	Moderator: Eva Nadal, Chair of Ph. Eur. Group of Experts 7 Challenges in establishment of reference standards for antibiotics Heiko Dueckert, EDQM, Council of Europe Obstacles faced during development of monographs for antibiotics with complex impurity profiles Martin Laven, Medical Products Agency,	Moderator: Salvador Cañigueral, Chair of Ph. Eur. Group of Experts 13B and Chair of the Ph. Eur. Commission An alternative and simplified approach to identification and test for minimum content of TCM herbal drugs by HPTLC Eike Reich, CAMAG, Switzerland HPLC assays for hydroxyanthracene	Moderator: Cathie Vielle, EDQM, Council of Europe The Future of PDG: expansion of PDG, maintenance of ICH Q4B and further harmonisation activities of the PDG Yujiro Kameyama, Japanese Pharmacopoeia, PMDA, Japan Dirk Leutner, EDQM, Council of Europe Kevin Moore, USP, USA			
Øyvind Holte, Chair of the PAT Working Party 2.2.46: adjustment of chromatographic conditions Anders Karlsson, AstraZeneca, Sweden	Sweden <b>CEPs for complex APIs - assessor's</b> <b>constraints and considerations</b> Ute Fischer, BfArm, Germany <b>Challenges in setting standards for non-</b>	derivatives replacing photometric assays Rudolf Bauer, Karl-Franzens-Universität Graz, Institute of Pharmaceutical Sciences, Austria Contaminant pyrrolizidine alkaloids	WHO perspective as observer to the PDG Luther Gwaza, WHO Motivation and expectations for harmonisation from the Indian Pharmacopoeia			
The challenge of N-nitrosamines detection in APIs - Input of chapter 2.5.42 Hervé Rebière, ANSM, France	<ul> <li>biological complexes (NBC) - iron sucrose story</li> <li>Erik Philipp, CSL Vifor Ltd., Switzerland</li> <li>Expectations and complexity in setting standards for polymeric excipients</li> <li>Johanna Eisele, Evonik Operations GmbH, Germany</li> </ul>	Robert Burman, Chair of the PA Working Party Essential oils Klaus Reh, Chair of Ph. Eur. Group of Experts 13A Nitrosamine and herbals: considerations from industry Barbara Steinhoff, German Medicines Manufacturers' Association (BAH), Germany	Priarmacopoeia         Rajeev Singh Raghuvanshi, IPC, India         Perspective of the Chinese         Pharmacopoeia         Song Zonghua, Chinese Pharmacopoeia         Commission (ChP)         Panel Discussion: Expectations and         future challenges for         pharmacopoeial harmonisation         Marieke van Dalen, APIC         Stephen Corrigan, IFPMA         Adrian Bone, IPEC Federation			

### INTERACTIVE SESSIONS

Time	Open Debate		Roundtables	
		Table 1: Monographs on biotherapeutic products Room: Londres 2	Table 4: Quality & functionality requirements of excipients Room: Londres 2	Table 7: Homeopathy & technical guide Room: Rome
11:00-11:40	Procedure 4 (P4) Moderator: Marija Malešević, Chair of the P4 Expert Group Auditorium: Cassin	Table 2: Pyrogenicity Room: Madrid 2 Table 3: Potential presence of <i>N</i> -nitrosamines in herbals Room: Madrid 2	Table 5: Monographs on medicinal products containing chemically defined APIs Room: Bruxelles Table 6: General chapters updates & needs Room: Madrid 2	Table 8: European Paediatric Formulary Room: BruxellesTable 9: Particulate contamination in parenteral preparations Room: Londres 2
				Table 10: Comparability ofalternative analytical proceduresRoom: Rome
11:40-11:50	•	Transfe	er participants 🖈	
		Table 1: Monographs on biotherapeutic products Room: Londres 2	Table 4: Quality & functionality requirements of excipients Room: Londres 2	Table 7: Homeopathy & technical guide Room: Rome
11:50-12:30	<b>3Rs</b> <b>Moderator</b> : Lukas Bruckner,	Table 2: PyrogenicityRoom: Madrid 2	Table 5: Monographs on medicinal products containing chemically defined APIs Room: Bruxelles	Table 8: European Paediatric Formulary Room: Bruxelles Table 9:
	Swiss Delegation of the Ph. Eur. Commission	Table 3: Potential presenceof N-nitrosamines in herbalsRoom: Madrid 2	Table 6: General chapters updates & needs Room: Madrid 2	Particulate contamination in parenteral preparations Room: Londres 2
	Auditorium: Cassin			Table 10: Comparability ofalternative analytical proceduresRoom: Rome

#### Day 2 - Afternoon - Tuesday, 20 September 2022

## FEATURED SESSIONS

Four sessions will run in parallel. Interpretation into French will not be provided during the featured sessions. 13:30-15:30

Session 1B	Session 5	Session 6	Session 7
Flexibility in the Ph. Eur.: a paradigm shift? (Part II)	Supporting microbiological and viral safety	Cell and gene therapies	Certification of Suitability
Auditorium: Cassin	Room: Londres 1	Room: Madrid 1	Room: Amsterdam
Moderator: Jaana Vesterinen, FIMEA, Finland	<b>Moderator</b> : Lukas Bruckner, Swiss Delegation Ph. Eur. Commission	Moderator: Marie-Thérese Duffour, ANSM, France	<b>Moderator</b> : Susanne Keitel, Former EDQM Director, Member of the CEP Steering Committee
<b>AQbD in the Ph. Eur.</b> Mihaela Buda, EDQM, Council of Europe	Ph. Eur. achievements in the control of extraneous agents for human and vet vaccines Catherine Lang & Gwenael Cirefice,	<b>Evolution in regulatory expectations</b> Violaine Closson-Carella, ANSM, France	<b>Recent updates regarding CEPs</b> Tiago Goncalves, EDQM, Council of Europe
Pharmacopoeial standard development for biotherapeutic products - industry perspective	EDQM, Council of Europe High Throughput Sequencing:	<b>Ph. Eur. activities in the cell and gene</b> <b>therapies field</b> Solène Le Maux & Olga Kolaj-Robin, EDQM,	Nitrosamines in active substances - A quality assessor's point of view Gernot Hirn, AGES, Austria
Erin Wang & Matthew Borer, Eli Lilly and Company, USA Flexible and robust monographs	How could the Ph. Eur. helps in the exercise to validate HTS methods? Siemon Ng, Notch Therapeutics,	Council of Europe <b>OMCL point of view</b> Juergen Scherer, Paul-Ehrlich-Institut,	<b>"CEP of the Future" Project</b> Nimet Filiz, EDQM, Council of Europe
Martijn Van der Plas, Medicines Evaluation Board, the Netherlands	Canada European Pharmacopoeia's Pyrogenicity project	Germany	The CEP of the Future – API manufacturers' perspective Marieke van Dalen, APIC, the Netherlands
<b>An industry perspective incl. AQbD</b> Cyrille Chery, UCB, Belgium	Emmanuelle Charton, EDQM, Council of Europe	<b>Case studies</b> Aline Le Tiec, Novartis, France	
	<b>Impact for pharma industry</b> Shahjahan Shaid, GSK Vaccines, Belgium		



## INTERACTIVE SESSIONS

Time	Open Debate		Roundtables	
		Table 11: Bioassay Room: Madrid 2	Table 14: Data analysis Room: Londres 2	Table 17: Technical guide Room: Rome
16:00-16:40	General Discussion on Communication channels	Table 12: Microbiologicalexamination of ATMPsRoom: Londres 2	Table 15: DNA reactive impurities: strategy for individual monographs	Table 18: Elemental impurities in plastic materials Room: Madrid 2
	Moderator: Evangelos Tasopoulos, EDQM, Council of Europe	Table 13: Challenge for herbalsdue to climate changeRoom: Bruxelles	Room: Madrid 2 Table 16: How to use/apply a monograph: tips and tricks Room: Londres 2	Table 19: Labelling section in dosageform monographsRoom: Rome
	Auditorium: Cassin			Table 20: Analytical Quality by Design (AQbD) and monographs Room: Bruxelles
16:40-16:50		Transfe	er participants 🛠	
	Unmet needs?	Table 11: BioassayRoom: Madrid 2	Table 14: Data analysis Room: Londres 2	Table 17: Technical guide Room: Rome
16:50-17:30	<b>Moderator:</b> Tobias Gosdschan, Swissmedic, Switzerland	Table 12: Microbiologicalexamination of ATMPsRoom: Londres 2	Table 15: DNA reactive impurities: strategy for individual monographs Room: Madrid 2	Table 18: Elemental impurities in plastic materials Room: Madrid 2
	Auditorium: Cassin	Table 13: Challenge for herbalsdue to climate changeRoom: Bruxelles	Table 16: How to use/apply a monograph: tips and tricks Room: Londres 2	Table 19: Labelling section in dosageform monographsRoom: Rome
				Table 20: Analytical Quality by Design (AQbD) and monographs Room: Bruxelles



#### **CLOSING PLENARY SESSION** Ŀ

### **EUROPEAN PHARMACOPOEIA: WHAT TO EXPECT FOR THE FUTURE**

#### Moderator:

Salvador Cañigueral, Chair of the European Pharmacopoeia Commission

- 08:30-09:40 Alternatives to Animal Testing (3Rs) Ph. Eur. Recent Achievements and Roadmap, Emmanuelle Charton, EDOM, Council of Europe BSP methods and standards to come, Lukas Bruckner, Swiss Delegation to the Ph. Eur. Commission Participation in international cooperation platforms/initiatives: WHO - NC3Rs initiatives, Richard Allen Isbrucker, WHO
- 09:40-10:10 Towards the 12th Edition of the European Pharmacopoeia: what's in the pipeline? An overview of current and future activities, Bruno Spieldenner and Emmanuelle Charton, EDOM, Council of Europe

10:10-10:40 Coffee break



10:40-11:35 Towards the 12<sup>th</sup> edition of the European Pharmacopoeia: new approaches and technologies in the quality control of medicines: next challenges for the European Pharmacopoeia Adapting Ph. Eur. to new approaches and technologies for quality control, Michel Ulmschneider, Chair of the Spectroscopy and Data Analysis (SDA) and General Methods (MG) Working Parties ICH Q5A (viral safety), High-throughput sequencing (HTS), Laurent Mallet, EDQM, Council of Europe

Activities in the field of nanomedicines, Gerrit Borchard, Chair of the Non-biological Complexes (NBC) Working Party

11:35-11:55 CEP of the Future and Future of CEPs

Helene Bruguera, EDQM, Council of Europe

11:55-12:15 Final Conclusions & Closing Remarks

Salvador Cañigueral, Chair of the European Pharmacopoeia Commission Petra Doerr, Director, EDOM, Council of Europe

12:15 **Close of the conference**